Key takeaways
- Remidio's AI tools for glaucoma and AMD receive CDSCO approval, expanding access to eye care.
- The tools function offline, making them suitable for remote areas with limited specialist access.
- Over 90% of glaucoma cases in India go undiagnosed, highlighting the need for early detection.
- Previous AI tool for diabetic retinopathy successfully screened nearly 250,000 patients in one year.
- CEO Anand Sivaraman emphasizes the importance of primary care diagnostics for timely interventions.
Remidio Innovative Solutions has received official approval from the Central Drugs Standard Control Organisation (CDSCO) for its AI-based tools to detect glaucoma and age-related macular degeneration (AMD).
These approvals follow the earlier success of Remidio’s AI tool for diabetic retinopathy, which helped screen nearly 2,50,000 patients in the past year.
Like their predecessors, the new glaucoma and AMD tools work without needing internet access, which means they can be used in remote or rural areas that often lack specialised eye care.
“The CDSCO's approval of our Medios HI Glaucoma AI and Medios HI AMD AI builds upon the foundation laid by our Medios HI DR AI, which was the first ophthalmic AI software to receive such approval in India,” Anand Sivaraman, CEO and founding director of Remidio, said.
The Medios HI Glaucoma AI tool checks for early signs of glaucoma by analysing key parts of the eye and showing results through easy-to-understand heat maps.
Research suggests that India, which has millions of glaucoma patients, yet more than 90% go undiagnosed, often leading to permanent vision loss.
The Medios HI AMD AI tool helps detect early signs of AMD, a common cause of vision loss in older adults.
The AI helps highlight abnormal areas in eye images so that healthcare providers can refer patients for further care in time.
“What excites us is their ability to bring specialist-grade diagnostics to the primary care level, empowering early intervention, particularly in settings where access to ophthalmologists is limited,” Dr Divya Rao, chief medical officer at Remidio, said.
These new AI tools have been tested in real hospitals and eye clinics and shown to perform accurately. They are built into Remidio’s portable eye camera device—the FOP NM 10—where a single tap can check for glaucoma, AMD, and diabetic retinopathy in just a few seconds.
“The Remidio fundus camera isn't just an imaging device; it’s a portable gateway to early detection and prevention of vision-threatening conditions, bringing quality eye care closer to those who need it most,” Dr R Kim, senior medical consultant at Aravind Eye Hospital in Madurai, said.
By making their solutions offline-ready and portable, the company is working to close the gap in vision care, especially in parts of the country where medical services are harder to reach.
